Mr. Rob Gamley reports

IMMUNOPRECISE INCREASES FINANCING TO $5.1 MILLION

Immunoprecise Antibodies Ltd., in conjunction with its acquisition of U-Protein Express BV, has increased its previously announced non-brokered private placement financing (see press release dated July 4, 2017) to 5.1 million shares at a price of $1 per share for gross proceeds of up to $5.1-million.

All securities issued in connection with the private placement will be subject to a four-month-and-one day statutory hold period. A finder's fee may be payable on the private placement.

Proceeds of the financing will be used for the acquisition of U-Protein and working capital purposes.

Completion of the private placement remains subject to the approval of the TSX Venture Exchange.

About Immunoprecise Antibodies Ltd.

Immunoprecise Antibodies provides its customers with custom antibody engineering and production services to support their research and development efforts.

Antibodies are naturally occurring proteins capable of binding to specific target molecules, or antigens. They have been used very widely in research assays, diagnostics, purification and therapeutics.

The target market for the company's antibody and peptide products includes organizations in the academic, biological, diagnostic and pharmaceutical fields. This is a large growing market that is expected to double in the next 10 years.

We seek Safe Harbor.